Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...
Nektar files $300M mixed securities shelf
EDT Nektar (NKTR) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.
The Globe and Mail5d
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Rahimi covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Tectonic Therapeutic, and Madrigal Pharmaceuticals. According to TipRanks, Rahimi has an average return of -0.8 ...
The Pharma Letter2d
IL-2s gain ground as US market heads for $4 billion by 2034
The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, ...
Investing3d
Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials
On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...
pharmaphorum4d
Nektar, BioMarin, and Alnylam top list of biotech M&A targets
The biggest firm on the list is Nektar Therapeutics, which is developing the promising immunotherapy NKTR-214. The report values San Francisco-based Nektar at $17 billion thanks to its multi ...
Yahoo Finance3d
Nektar Therapeutics (NKTR)
At close: March 28 at 4:00:00 PM EDT ...